Compare Ascendis Pharma A/S (ASND) vs Oscar Health Inc (OSCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Oscar Health Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Oscar Health Inc trades at $30.34 (market cap $9.21B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap. Which is the better fit depends on your goals.
| ASND | OSCR | |
|---|---|---|
Market Cap | $17.74B | $9.21B |
Sector | Health | Health |
52-Week High | $277.18 | $32.18 |
52-Week Low | $163.32 | $10.85 |
Enterprise Value | $18.11B | $4.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
OSCR trades at $30.54, down 2.12% today but up significantly year-to-date. Technicals are bullish with moving averages supporting the uptrend, while oscillators show neutral momentum. Fundamentally, revenue grew to $11.70B in 2025 with a net loss of $443M, but 2026 guidance projects improved profitability. Recent news highlights strong Q1 2026 earnings beat and reaffirmed growth targets at industry conferences.
Outlook remains optimistic due to strong revenue growth and operational improvements, but risks include persistent net losses and competitive pressures. Analyst consensus is mixed with a $22.50 price target below current levels, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
